Cardiovascular non-Adherence Tailored Intervention (CATI) care programme

Randomized controlled trial to test the (cost)-effectiveness of a patient tailored intervention programme (CATI) to enhance adherence to cardiovascular medication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26090

Enrollment

176

Registered

2015-02-02

Start date

2013-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular medication non-adherence

Interventions

The CATI care programme is a patient tailored intervention programme to enhance adherence to cardiovascular medication, incorporating the identification of barriers for non-adherence and offering inte

improving knowledge, for instance about the use and effectiveness of the medication

or providing tools, for instance reminder services and pillboxes. • Consultation upon initiation The pharmacist invites

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age 45-75 years 2) Using cardiovascular medication i.e. antihypertensive and/or lipid-lowering drugs 3) Meeting all three inclusion criteria described below: a. Being refill non-adherent according to pharmacy dispensing data b. Being non-adherent according to a self-report questionnaire c. Having abnormal clinical rates to low-density lipoprotein concentration and/or blood pressure

Exclusion criteria

Exclusion criteria: 1) Being unable to speak or read Dutch

Design outcomes

Primary

Measure	Time frame
Self-reported medication adherence is the primary outcome measure. Medication adherence will be assessed at baseline, at follow-up and at endline. Differences between the medication non-adherence at baseline and at endline will be compared. Medication adherence will be assessed with the MARS-5 questionnaire.	—

Secondary

Measure	Time frame
LDL concentration and BP are clinical secondary outcome measures. The pre-measurement will be included in the selection procedure at baseline and the post-measurement will be assessed after six months. LDL concentration will be measured with a finger prick of blood. Blood pressure will be measured with a sphygmomanometer. Quality of life will be assessed by using the Short Form 12 Health Survey (SF-12) questionnaire. The SF-12 questionnaire consists of 12 questions covering eight dimension of health i.e. general health perception, physical functioning, limitations due to physical health problems, bodily pain, vitality, social functioning, emotional functioning and general mental health. The eight domains can produce two summary scores for physical health (Physical Component Score, PCS) and mental health (Mental Component Score, MCS).	—

Measure

Time frame

LDL concentration and BP are clinical secondary outcome measures. The pre-measurement will be included in the selection procedure at baseline and the post-measurement will be assessed after six months. LDL concentration will be measured with a finger prick of blood. Blood pressure will be measured with a sphygmomanometer. Quality of life will be assessed by using the Short Form 12 Health Survey (SF-12) questionnaire. The SF-12 questionnaire consists of 12 questions covering eight dimension of health i.e. general health perception, physical functioning, limitations due to physical health problems, bodily pain, vitality, social functioning, emotional functioning and general mental health. The eight domains can produce two summary scores for physical health (Physical Component Score, PCS) and mental health (Mental Component Score, MCS).

—

Contacts

Public ContactDanielle van der Laan

Van der Boechorststraat 7

d.vanderlaan1@vumc.nl+31204441715

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)